Results 191 to 200 of about 63,889 (276)

Drug‐Induced Liver Injury During Treatment With Tocilizumab: A Case Report of an Atypical Pattern Lesion

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Tocilizumab is an interleukin‐6 (IL‐6) receptor antagonist indicated for various rheumatologic conditions. While hepatotoxicity is a recognized adverse effect, it predominantly manifests as hepatocellular injury. We report a rare case of drug‐induced liver injury (DILI) presenting with a cholestatic pattern and cholangitis features in a 75 ...
Louis‐Edmond Barbaro, Nouha Ben Othman, Delphine Viard, Fanny Rocher, Elliot Ewig, Raja Mroue, Claire Amigues, Alexandre O. Gérard   +7 more
wiley   +1 more source

Editorial: Advances in the treatment of acute severe ulcerative colitis. [PDF]

Front Gastroenterol (Lausanne)
Karunadasa H, O'Connor R, Con D, Srinivasan A, Vasudevan A.   +4 more
europepmc   +1 more source

Lowering the C‐Reactive Protein (CRP) Threshold Improves Risk Stratification in Acute Ulcerative Colitis: A Propensity‐Matched Analysis

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 7, Page 985-1000, October 2026.
In 503 acute UC admissions, colectomy risk was equivalent between TWC‐positive ASUC and NASUC inpatients after propensity score matching for objective disease severity and treatment exposure; lowering the CRP threshold to ≥ 12 mg/L reclassified 26% of NASUC cases as ASUC and captured 43% of those requiring colectomy within one year, improving ...
Amirah Etchegaray, Naeman Goetz, Katherine Hanigan, Jennifer Phillips, Rina Kumar, George Tambakis, Graham Radford‐Smith, Gareth Walker, Anthony Croft   +8 more
wiley   +1 more source

Common Causes of Drug-Induced Liver Injury in 2025. [PDF]

Turk J Gastroenterol
Björnsson ES.
europepmc   +1 more source

Inflammatory Bowel Disease Is Associated With an Increased Risk of End‐Stage Renal Disease: A Population‐Based Cohort Study

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 8, Page 1110-1122, October 2026.
In a retrospective population‐based cohort study using the University of Manitoba IBD Epidemiology Database, persons with IBD have an increased risk of ESRD by nearly 50%, with CD showing greater risk than UC. Bowel surgery, allopurinol use and oral steroid therapy are important predictors, emphasising the necessity of careful renal monitoring in IBD ...
Onuma Sattayalertyanyong, Zoann Nugent, Bryce Barr, Keevin N. Bernstein, Charles N. Bernstein   +4 more
wiley   +1 more source

Effective Treatment of Audiovestibular Involvement in Cogan's Syndrome with Biologics and Hyperbaric Oxygen Therapy. [PDF]

Eur J Case Rep Intern Med
Biadacz-Sadurska A, Krefta A, Tłustochowicz W.   +2 more
europepmc   +1 more source

Review article: Immunosuppression in Decompensated Autoimmune Hepatitis Cirrhosis ‐ To Suppress or Not to Suppress?

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 7, Page 897-918, October 2026.
Individualized assessment identifies patients with decompensated autoimmune hepatitis cirrhosis who are likely to benefit from a time‐limited trial of immunosuppression versus those requiring immediate liver transplant evaluation. Early objective response monitoring (bilirubin, MELD‐Na and AST/ALT) guides continuation of immunosuppression, promotes ...
Pedro Robson Costa Passos, Valbert Oliveira Costa Filho, Guilherme Grossi Lopes Cançado   +2 more
wiley   +1 more source

Review Article: Immune Effector Cell‐Mediated Enterocolitis Following CAR‐T Cell Therapy—Clinical Features, Pathophysiology and Management

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 8, Page 1046-1057, October 2026.
Immune effector cell‐mediated enterocolitis is an emerging complication of CAR‐T therapy. This review summarizes its epidemiology, pathophysiology, diagnosis, endoscopic and histopathologic features, and evidence‐based management, emphasizing early recognition, multidisciplinary intervention, and step‐up therapy.
John A. Damianos, Yi Lin, Zongming Eric Chen, Kenneth J. C. Lim, Navreet M. Chowla   +4 more
wiley   +1 more source

Liver Injury From Medications Used for Treating Inflammatory Bowel Disease: The Drug-Induced Liver Injury Network Experience. [PDF]

Liver Int
Gopalakrishna H, Gu J, Li YJ, Barnhart H, Halegoua-DeMarzio D, Bonkovsky HL, Barritt AS, Molleston JP, Chalasani NP, Ghabril M.   +9 more
europepmc   +1 more source

Clinical Phenotypes, Treatment, and Outcomes of Rheumatic Immune–Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitors: A Rheumatologists‐Referred Multicenter German Registry Cohort

ACR Open Rheumatology, Volume 8, Issue 9, September 2026.
Objective Immune checkpoint inhibitors (ICIs) induce a broad range of immune‐related adverse events (irAEs), including rheumatic manifestations. Evidence from dedicated rheumatology cohorts on the clinical spectrum, severity, treatment, and outcomes of rheumatic irAEs (rh‐irAEs) remains limited.
Didzis Gailis, Fabian T.H. Ullrich, Sophia Dombret, Marc Schmalzing, Rebecca Hasseli‐Fräbel, Torsten Witte, Thea Thiele, Uta Kiltz, Mara Oleszowsky, Marcel Müller, Karolina Gente, Christof Specker, Matthias B. Thaler, Alla Skapenko, Hendrik Schulze‐Koops   +14 more
wiley   +1 more source